As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, Medicare director Meena Seshamani, and FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni have retired or intend to retire prior to Trump's inauguration on Jan. 20.

Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country is healthier and stronger."

In a wide-ranging interview, Xavier Becerra, President Biden’s health secretary, defended his tenure and hinted that he might run for governor of California.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Changes may be on the horizon regarding the cost of diabetes and weight loss drug titans like Ozempic and Wegovy. The Biden administration has announced the next round of prescription drugs selected for Medicare price negotiations.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

The number of people signing up for Marketplace coverage has surpassed 24 million, an all-time high, breaking last year’s record. I’m proud of the work done by the Biden-Harris Administration and the U.

Obamacare enrollments in health insurance exchanges for the 2025 enrollment period have reached 24.2M, an all-time high. Read more here.